Revance Therapeutics (RVNC)
(Real Time Quote from BATS)
$3.78 USD
+0.02 (0.53%)
Updated Jul 26, 2024 12:40 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RVNC 3.78 +0.02(0.53%)
Will RVNC be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RVNC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RVNC
Revance Therapeutics (RVNC) Loses -18.85% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Lags Revenue Estimates
RVNC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Krystal Biotech, Inc. (KRYS) Q1 Earnings and Revenues Miss Estimates
Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates
Qiagen (QGEN) Surpasses Q1 Earnings and Revenue Estimates
Other News for RVNC
Revance Therapeutics: Problems Mounting Amid Legal And Financial Woes
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Revance to Participate in Upcoming Investor Conferences
The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains
Barclays Sticks to Its Buy Rating for Revance Therapeutics (RVNC)